✦ LIBER ✦

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response

✍ Scribed by Brian L. Pearlman; Carole Ehleben

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 271 KB
Volume: 52
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.23925

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm

Pegylated interferon alfa and ribavirin

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

✍ Olav Dalgard; Kristian Bjøro; Helmer Ring-Larsen; Einar Bjornsson; Mona Holberg- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 1 views

A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial. In the trial, 428

Prediction of response to peginterferon-

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v

Impact of high-dose peginterferon alfa-2

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

✍ Stuart K. Roberts; Martin D. Weltman; Darrell H. G. Crawford; Geoffrey W. McCaug 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 1 views

This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFNalpha-2a) for the first 12 weeks would increase early and sustained virological response (SVR) rates in patients with chronic hepatitis C genotype 1. Eight hundred ninety-six patients were randomized 1:1 to 360 microg (n =

Placebo-controlled trial of 400 mg amant

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection

✍ Michael von Wagner; Wolf Peter Hofmann; Gerlinde Teuber; Thomas Berg; Tobias Goe 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

The impact of amantadine on virologic response rates of interferon-based treatment of chronic hepatitis C is controversial. The aim of this study was to compare virological response rates in patients with chronic hepatitis C virus (HCV)-1 infection treated with 400 mg amantadine or placebo in combin

A randomized, prospective trial of ribav

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3

✍ Peter Ferenci; Harald Brunner; Hermann Laferl; Thomas-Matthias Scherzer; Andreas 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

öschenberger, 10 for the Austrian Hepatitis Study Group We compared the efficacy and tolerability of 24 weeks of treatment with ribavirin 800 mg/day (group A) or 400 mg/day (group B) plus peginterferon alfa-2a 180 g/week in treatment-naive patients infected with hepatitis C virus (HCV) genotype 2 o